SOLICITATION NOTICE
B -- Services regarding Conducting sequential HPV serology
- Notice Date
- 8/22/2007
- Notice Type
- Solicitation Notice
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852, UNITED STATES
- ZIP Code
- 00000
- Solicitation Number
- Reference-Number-NCI-70138-NG
- Response Due
- 9/7/2007
- Archive Date
- 9/22/2007
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Genetic Epidemiology Branch (GEB) plans to procure on a sole source basis in accordance with 13.106-(b)(1), services regarding: Conducting sequential HPV serology before and at diagnosis of cutaneous SCC, using serum samples from 132 cases from the Skin Cancer Prevention Study with Dartmouth Medical School, One Medical Center Drive, 7927 Rubin Building, Lebanon, NH 03756. The supplies and services herein are being procured in accordance with the simplified acquisition procedures as authorized by FAR Part 13. The North American Industry Classification System code is 541380 and the business size standard is $11M. The purpose of this requisition is to provide service in order to investigate the natural history of human papilloma virus (HPV) in the etiology of cutaneous squamous cell carcinoma (SCC) in the Skin Cancer Prevention Trial. Services shall be provided for one year from date of award. The skin cancer prevention trial evaluated the risk of subsequent basal cell carcinoma (BCC) and SCC cell skin among patients with a prior history of these tumors to examine these risks in relation to the patients characteristics and life-style factors. The study followed 1,805 individuals who were diagnosed with BCC or SCC of the skin from January 1980 and February 1986 and were free of skin cancer at study entry. Annual skin examinations were conducted and skin biopsies were performed if patients developed skin cancers. One hundred and thirty-two individuals developed SCC during the study period. Family studies of patients with epidermodysplasia verruciformis (EV), a rare inherited disorder characterized by early onset of cutaneous flat-to-papillomatous reddish-brown pigmented plaques with susceptibility to early onset NMSC, have impaired cellular immunity that makes them susceptible to widespread chronic infection with HPV 5 and 8. Initial serologic studies also provide evidence that HPV is a potential etiologic factor in NMSC. However, these studies were small and only investigated a limited number of HPV types. In this requirement, the contractor shall investigate the hypothesis that HPV is involved in the etiology of cutaneous SCC. All SCC cases and control serum specimens shall be analyzed by the contractor for antibodies to the major capsid protein L1 of HPV types 1, 2, 3, 5, 6, 8, 9, 10, 15, 16, 20, 24, 32, 36, 38, and 57. The serology data shall be analyzed by the contracting laboratory. This study will assess the risk of SCC with HPV and will evaluate sequential HPV serology before and at or after diagnosis of SCC providing critical information about the natural history of HPV in the etiology of SCC. Dartmouth Medical School shall investigate the natural history of human papilloma virus (HPV) in the etiology of cutaneous squamous cell carcinoma (SCC) in the Skin Cancer Prevention Trial. Sequential HPV serology before and at diagnosis of cutaneous SCC will be conducted, using serum samples from 132 cases from the Skin Cancer Prevention Study. Dartmouth Medical School owns the data, blood and serum specimens collected during the Skin Cancer Prevention Study. NCI will also randomly select controls for each study (age and gender matched). The contractor shall provide the serum from all the cases and controls from the Skin Cancer Prevention Study. NCI plans to screen serum samples of individuals with and without SCC for HPV for antibodies to a variety of HPV types. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party has the unique capabilities, resources and personnel to perform the requirement. Capability statements must be received in the contracting office by 1:00 PM EDT, on September 7, 2007. For further information please contact Malinda Holdcraft, Contract Specialist via electronic mail at holdcram@exchange.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Reference NCI-70138-NG on all correspondence.
- Record
- SN01380832-W 20070824/070822220619 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |